As a follow up to my last post about the three posters that appeared at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium meeting I am going to share with you a video interview with Dr. Chadi Nabhan. Dr. Nabhan talks about his presentation about the phase III results of the Provenge IMPACT [...]
The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]
Radium-223 choride, also known as Alpharadin, has demonstrated a small but statistically significant survival benefit in men with symptomatic metastatic castrate resistant prostate cancer (mCRPC). My expectation is that it will be approved by the FDA some time later this year. Additionally, my hope is that it will also be approved Europe. To read more [...]
The late-stage trial of Revlimid (lenalidomide) for the treatment of advanced prostate cancer has been discontinued after preliminary data shows that it does not extend survival! The independent monitoring committee recommended that the pivotal Phase III Mainsail trial be halted after it determined that adding Revlimid to standard treatments would not significantly increase the overall [...]
Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, “ON THE HORIZON.” OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data from their phase 2 trials evaluating their investigational compound OGX-427, in prostate and bladder cancer. The data will be presented [...]